AllergyTalk

Today we joined by Dr. Shyam Joshi, an associate professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch! We will be reviewing the November-December 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. And for those currently listening to the audio version, we are now releasing a video versions of AllergyTalk! Please visit the ACAAI YouTube channel at https://www.youtube.com/@allergists To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Paging ChatGPT: Potential and Limitations: Can ChatGPT provide parent education for oral immunotherapy?  2024 Consensus Report: A New Consensus Definition for Anaphylaxis: Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GA(2)LEN project.  Zileuton Prevents Food Allergen Induced Anaphylaxis in Mice: Cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice. Please rate our podcast on Apple Podcasts or YouTube! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Part 3: Biologics in IgE-Mediated Food Allergy: Expanding the Toolbox  This episode examines the growing role of biologic therapies like omalizumab in managing complex food allergies, reviewing trial data, mechanisms, and practical guidance for collaborative care. Host Gerald Lee, MD, FACAAI, is joined by Brian P. Vickery, MD, Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta, and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai. For more information on this topic, please visit: Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332 Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034 Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918 Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014 Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382 Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. This podcast miniseries is supported by Genentech.

Part 2: Immunotherapy for IgE-Mediated Food Allergy: OIT, SLIT & EPIT  This episode explores FDA-approved and emerging immunotherapies for food allergy—OIT, SLIT, and EPIT—highlighting their indications, efficacy, safety, and role in shared decision-making. Host Gerald Lee, MD, FACAAI, is joined by Edwin H. Kim, MD, FACAAI, Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai. For more information on this topic, please visit: Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332 Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034 Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918 Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014 Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382 Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. This podcast miniseries is supported by Genentech.

Part 1: Diagnosis, Prevention & Early Management  This episode explores how to accurately diagnose and manage food allergies in primary care, covering testing indications, referral criteria, prevention strategies, and risk stratification. Host Gerald Lee, MD, FACAAI, is joined by Brian P. Vickery, MD, Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta, and Edwin H. Kim, MD, FACAAI, Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine. For more information on this topic, please visit: Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332 Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034 Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918 Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014 Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382 Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. This podcast miniseries is supported by Genentech.

Dr. Timothy Chow, Assistant Professor at UT Southwestern and an Assistant Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2025 issue of AllergyWatch®. Articles Reviewed: Prenatal indoor PM2.5 exposure is associated with worse maternal asthma health and lung function Want to help your patients with food allergy anxiety? Do proximity challenges! Tiotropium initiation and dementia risk in chronic obstructive pulmonary disease Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Timothy Chow, Assistant Professor at UT Southwestern and an Assistant Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2025 issue of AllergyWatch®. Articles Reviewed: Integrated phase 1 pharmacokinetics and pharmacodynamics of epinephrine administered through sublingual film, autoinjector, or manual injection Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies Peanut oral immunotherapy in children with high-threshold peanut allergy Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the May/June 2025 issue of AllergyWatch®. Articles Reviewed: Outcomes of intravenous immunoglobulin treatment of immunocompromised patients with viral respiratory infections A 1-Year Weight Management Program for Difficult-to-Treat Asthma With Obesity: A Randomized Controlled Study Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and and Dr. Stanley Fineman, MD, MBA reviewed the May/June 2025 issue of AllergyWatch®. Articles Reviewed: Association of Allergy Specialty Care and Asthma Outcomes for Medicaid-Enrolled Children Race-Specific and Race-Neutral Equations for Lung Function and Asthma Diagnosis in Black Children Anaphylactic degranulation by mast cells requires the mobilization of inflammasome components Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures:  Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Sarah Spriet, DO, Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the January/February 2025 issue of AllergyWatch®. Articles Reviewed: Persistent cat ownership and asthma in a longitudinal study of Puerto Rican youth The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children – A pivotal phase III trial Awareness and application of United States food allergy prevention guidelines among pediatricians and other clinicians Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose Sarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Special Episode ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to discuss advice on landing your first position. Continuing the conversation from Part 1, in this episode, our experts cover how to narrow down your choices, make sense of contracts and negotiations, decide whether to involve a contract lawyer, and plan a smooth transition into your next chapter. Earn CME credit for listening to this episode! Free for College members! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to disclose Kylie Jungles, MD: No relevant financial relationships with ineligible companies to disclose Melinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Special Episode ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to share essential tips for fellows-in-training starting their job search. Learn how to choose the right practice setting, create a strategic job search plan, and interview with confidence. Earn CME credit for listening to this episode! Free for College members! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to disclose Kylie Jungles, MD: No relevant financial relationships with ineligible companies to disclose Melinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Special Episode On May 16, 2025, the FDA issued an alert regarding a rare but serious side effect of severe pruritus after discontinuing long-term use of cetirizine and levocetirizine. In this episode, we’ll discuss the background of this important announcement and what it means for our patients! Michael S. Blaiss, MD, Clinical Professor of Pediatrics at the Medical College of Georgia and past-president and former Executive Medical Director of the American College of Allergy, Asthma, and Immunology. He has been a consultant for multiple companies manufacturing second generation antihistamines. Dr. Blaiss was joined by host Dr. Gerald Lee, MD, FACAAI. Resources: FDA Drug Safety Communication on Cetirizine and Levocetirizine ACAAI Advice on Speaking Points Regarding FDA Alert Previous articles describing this side effect: Unbearable Pruritus After Withdrawal of (Levo)cetirizine Pruritus after discontinuation of cetirizine Make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Sarah Spriet, DO, Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the January/February 2025 issue of AllergyWatch®. Articles Reviewed: A novel syndrome of silent rhinovirus-associated bronchoalveolitis in children with recurrent wheeze Effects of moderate- versus vigorous-intensity exercise training on asthma outcomes in adults Human Neutrophils Couple Nitric Oxide Production and Extracellular Trap Formation in Allergic Asthma Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: Genentech Sarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.  

Dr. Iris Otani, MD, an associate professor of medicine at UCSF and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the November/December 2024 issue AllergyWatch®. Articles Reviewed: Frequencies and predictors of subcutaneous and intraosseous injection with 4 epinephrine autoinjector devices Forecasting daily total pollen concentrations on a global scale Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: Genentech Iris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Iris Otani, MD, an associate professor of medicine at UCSF and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the November/December 2024 issue AllergyWatch®. Articles Reviewed: Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures:  Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: Genentech Iris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Vivian Hernandez Trujillo, MD, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of AllergyWatch and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2024 issue AllergyWatch. Articles Reviewed: The mental health burden of food allergies: Insights from patients and their caregivers from the Food Allergy Research & Education (FARE) Patient Registry Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders Bronchoconstriction damages airway epithelia by crowding-induced excess cell extrusion The speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Hernandez Trujillo: Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda Consultant: Pharming, Kaleo Speaker: CSL, Takeda, Kaleo Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Welcome to Season Three of Allergytalk! Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: IgE to cross-reactive carbohydrate determinants (CCD) in childhood: Prevalence, risk factors, putative origins.  Activation of basophils in children with food allergies by blood from donors ingesting the corresponding food. Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.   Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Hernandez Trujillo: Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda Consultant/Speaker: Kaleo Consultant: Allergy & Asthma Network, Pharming Speaker: CSL, Takeda  

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI   Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.   Learning Objective: After listening to this podcast episode, participants should be better able to: Employ strategies for long-term prophylaxis. References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022   Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast   Aleena Banerji, MD Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda Researcher: Astria, Ionis, Intellia   Jonathan A. Bernstein, MD, FACAAI Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva   This podcast miniseries is supported by a grant from Takeda.

Episode 2: Overcoming Barriers in HAE Treatment   Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI   This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.   Learning Objective: After listening to this podcast episode, participants should be better able to: Create effective treatment plans for their specific population (minority, rural, urban)   References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022   Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast   Jonathan A. Bernstein, MD, FACAAI Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva   Timothy J. Craig, DO, FACAAI Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda Independent Contractor: Kalvista, Phavaris Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda   This podcast miniseries is supported by a grant from Takeda.

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed. Learning Objective: After listening to this podcast episode, participants should be better able to: Diagnose pediatric HAE accurately References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022 Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast   Aleena Banerji, MD Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda Researcher: Astria, Ionis, Intellia   Timothy J. Craig, DO, FACAAI Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda Independent Contractor: Kalvista, Phavaris Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda   This podcast miniseries is supported by a grant from Takeda.